



ApoE Genotype Test (for Type III Hyperlipoproteinemia):

1. Feussner G et al. (1993). Clinical features of type III hyperlipoproteinemia: analysis of 64 patients. *Clin Invest* 71:362-366.
2. Mahley RW et al. (1995). In: Scriver CR et al. (eds) *The Molecular and Metabolic Basis of Inherited Disease*, vol 3, pp. 1953-1980.
3. Richard P et al. (1994). Common and rare genotypes of human apolipoprotein E determined by specific restriction profiles of polymerase chain reaction-amplified DNA. *Clin Chem* 40:24-29.
4. Walden CC et al. (1993). DNA analysis in type III hyperlipoproteinemia. *Can Med Assoc J* 149:445-446.
5. Wilson PW et al. (1994). Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. *JAMA* 272: 1661-1671.

Celiac Disease DNA Test:

1. Farrell RJ and Kelly CP. (2002). Celiac sprue. *N Eng J Med* 346:180-188.
2. Fasano A et al. (2003). Prevalence of celiac disease in at-risk and not-at-risk groups in the United States. *Arch Intern Med* 163:286-292.
3. Fernandez-Arquero M et al. (1995). HLA-linked genes acting as additive susceptibility factors in celiac disease. *Hum Immunol* 42:295-300.
4. Sollid LM. (2000). Molecular basis of celiac disease. *Annu Rev Immunol* 18:53-81.
5. Sollid LM. (2002). Coeliac disease: dissecting a complex inflammatory disorder. *Nat Rev Immunol* 2:647-655.

Cystic Fibrosis DNA Test:

1. American College of Obstetricians and Gynecologists, American College of Medical Genetics. (2001). *Clinical and Laboratory Guidelines: Preconception and prenatal carrier screening for cystic fibrosis*. ACOG, Washington, DC.
2. Grody WW et al. Subcommittee on Cystic Fibrosis Screening, Accreditation of Genetic Services Committee, ACMG (2001). ACMG Statement. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. *Genet in Med* 3:149-154.
3. Genetic testing for cystic fibrosis. NIH Consensus Development Conference Statement on genetic testing for cystic fibrosis. (1999) *Arch Intern Med* 159:1529-1539.
4. Richards CS et al. (2002). Standards and Guidelines for CFTR Mutation Testing. *Genet in Med* 4:379-391.
5. Haddow JE and Palomaki GE. (2002). Population-based prenatal screening for cystic fibrosis via carrier testing: ACCE review. www.cdc.gov.

Factor V Leiden DNA Test:

1. Bertina RM et al. (1994). Mutation in blood coagulation factor V associated with resistance to activated protein C. *Nature* 369:64-67.
2. Zoller B et al. (1994). Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. *J Clin Invest* 94:2521-2524.
3. Svensson PJ et al. (1994). Resistance to activated protein C as a basis for venous thrombosis. *N Engl J Med* 330:517-522.
4. Ridker PM et al. (1995). Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. *N Engl J Med* 332:912-917.
5. Rosendaal FR et al. (1995). High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). *Blood* 85:1504-1508.
6. Koeleman BP et al. (1994). Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. *Blood* 84:1031-1035.
7. Vandembroucke JP et al. (1994). Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. *Lancet* 344:1453-1457.
8. Hellgren M et al. (1995). Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. *Am J Obstet Gynecol* 173:210-213.
9. Poort SR et al. (1996). A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. *Blood* 88:3698-3703.
10. Grody WW et al. (2001). American College of Medical Genetics consensus statement on factor V Leiden mutation testing. *Genet Med* 3:139-148.



Factor V R2 DNA Test:

1. Faioni EM et al. (1999) Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). *Blood* 94:3062-3066.
2. Lunghi B et al. (1996) Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma. *Thromb Haemost* 75:45-48.
3. Alhenc-Gelas M et al. (1999) The factor V gene A4070G mutation and the risk of venous thrombosis. *Thromb Haemost* 81:193-197.
4. Bernardi F et al. (1997) A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. *Blood* 90:1552-1557.
5. de Visser M et al. (1999) A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. *Blood* 93:1271-1276.

Fragile X DNA Test:

1. Verkerk AJ et al. (1991). Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. *Cell* 65:905-914.
2. Pieretti M et al. (1991). Absence of expression of the FMR-1 gene in fragile X syndrome. *Cell* 66:817-822.
3. Taylor AK et al (1994). Molecular predictors of cognitive involvement in female carriers of fragile X syndrome. *JAMA* 271:507-514.
4. Fu YH et al. (1991). Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. *Cell* 67:1047-1058.
5. Eichler EE et al. (1994). Length of uninterrupted CGG repeats determines instability in the FMR1 gene. *Nat Genet* 8:88-94.
6. Nolin SL et al. (1996). Familial transmission of the FMR1 CGG repeat. *Am J of Hum Genet* 59:1252-1261.
7. Jin P and Warren ST. (2000). Understanding the molecular basis of fragile X syndrome. *Hum Mol Genet* 9:901-908.

Fragile X Protein (FMRP) Test:

1. Tassone F et al. (1999). FMRP expression as a potential prognostic indicator in fragile X syndrome. *Am J Med Genet* 84:250-261.
2. Willemsen R et al. (1997b). Rapid antibody test for diagnosing fragile X syndrome: a validation of the technique. *Hum Genet* 4:140-142.

Hemochromatosis DNA Test:

1. Bacon BR et al. (1999). Molecular medicine and hemochromatosis: at the crossroads. *Gastroenterology* 116:193-207.
2. Feder JN et al. (1996). A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. *Nat Genet* 13:99-408.
3. Jouanolle AM et al. (1996). Haemochromatosis and HLA-H. *Nat Genet* 14:251-252.
4. Kaikov Y et al. (1992). Primary hemochromatosis in children: report of three newly diagnosed cases and review of the pediatric literature. *Pediatrics* 90:37-42.
5. Shaheen NJ et al. (1998). Clinical characteristics of hereditary hemochromatosis patients who lack the C282Y mutation. *Hepatology* 28:526-529.
6. Witte DL et al. (1996). Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. *Clin Chim Acta* 245:139-200.

HLA-B27 DNA Test:

1. Ball EJ and Khan MA. (2001) HLA-B27 polymorphism. *Joint Bone Spine* 68:378-382.
2. Brodsky FM. (1997). Antigen presentation and the major histocompatibility complex. In: Stites DP, Terr AI, Parslow TG (eds). *Medical Immunology*, 9th ed., Appleton & Lange, Stamford, CT, pp. 83-94.
3. Cush JJ and Lipsky P. (1996). The spondylarthropathies. In: Bennett JC and Plum F (eds). *Cecil Textbook of Medicine*, 20th ed., Philadelphia, WB Saunders Co., pp. 1466-1472.
4. Khan MA. (2002). Update on spondyloarthropathies. *Ann Intern Med* 136:896-907.



MTHFR DNA Test:

1. Arruda V et al. (1997). The mutation Ala677-->Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. *Thromb Haemost* 77: 818-821.
2. Cattaneo M. (1999). Hyperhomocysteinemia, atherosclerosis and thrombosis. *Thromb Haemost* 81:165-176.
3. Frosst P et al. (1995). A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. *Nat Genet* 10:111-113.
4. Jacques P et al. (1996). Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. *Circulation* 93:7-9.
6. van der Put NM et al. (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? *Am J Hum Genet* 62:1044-1051.
7. Szczeklik A et al. (2001). Mutation A1298C of methylenetetrahydrofolate reductase: risk for early coronary disease not associated with hyperhomocysteinemia. *Am J Med Genet* 101:36-39.

Narcolepsy DNA Test:

1. Hong SC et al. (2000). Clinical and polysomnographic features in DQB1*0602 positive and negative narcolepsy patients: results from the modafinil clinical trial. *Sleep Med* 1:33-39.
2. Lin L et al. (2001). Narcolepsy and the HLA region. *J of Neuroimmunol* 117:9-20.
3. Nishino SE et al. (2001). Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. *Ann Neurol* 50:381-388.
4. Thorpy M et al. (2001). Current concepts in the etiology, diagnosis and treatment of narcolepsy. *Sleep Med* 2:5-17.

Prothrombin (Factor II) DNA Test:

1. Poort SR et al. (1996). A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. *Blood* 88:3698-3703.
2. Rosendaal FR et al. (1997). A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. *Blood* 90:1747-1750.
3. Cumming AM et al. (1997). The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population. *Br J Haem.* 98:353-355.
4. Hillarp A et al. (1997). The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. *Thromb Haemost* 78:990-992.
5. Rosendaal FR (1997). Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. *Thromb Haemost* 78:1-6.

PST® Genetic Test for Susceptibility to Periodontal Disease:

1. McGuire MK et al (1999). Prognosis versus actual outcome. IV. The effectiveness of clinical parameters and IL-1 genotype in accurately predicting prognoses and tooth survival. *J Periodontol* 70:49-56.
2. Kornman KS et al (1997). The interleukin-1 genotype as a severity factor in adult periodontal disease. *J Clin Periodontol* 24:72-77.
3. McDevitt MJ et al (2000). Interleukin-1 genetic association with periodontitis in clinical practice. *J Periodontol* 71:156-163.
4. Risk Assessment and the role of genetics in periodontal disease. (1999). Interleukin Genetics, Inc. Reference list available upon request.

PST® is a registered service mark of Interleukin Genetics, Inc.

PST® genotyping is performed under a license from Interleukin Genetics, Inc.

kimball genetics